AmCad BioMed Corporation (TPEX:4188)

Taiwan · Delayed Price · Currency is TWD

14.00

+0.20 (1.45%)

Sep 18, 2026, 1:30 PM CST

Market Cap	874.00M -11.8%
Revenue (ttm)	28.60M -34.4%
Net Income	-52.66M
EPS	-0.83
Shares Out	63.33M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	97,779
Open	13.50
Previous Close	13.80
Day's Range	13.50 - 14.50
52-Week Range	9.06 - 17.65
Beta	0.39
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 5, 2026

About AmCad BioMed

AmCad BioMed Corporation develops computer-aided detection and diagnosis (CAD) software devices primarily in Taiwan. It offers products for early detection and diagnosis of various diseases. The company’s products include AmCAD-UT Detection, a CAD device for ultrasound images of thyroid nodules; and AmCAD-UO for detection of obstructive sleep apnea on awake patients. It also developing AmCAD-US, a software device for visualizing and quantifying statistical distributions of backscattered signals echoed by tissue compositions in the body from FDA... [Read more]

Industry Medical Devices

Sector Healthcare

Founded 2008

Employees 34

Stock Exchange Taipei Exchange

Ticker Symbol 4188

Full Company Profile

Financial Performance

In 2025, AmCad BioMed's revenue was 30.44 million, a decrease of -42.69% compared to the previous year's 53.11 million. Losses were -55.72 million, 10.2% more than in 2024.

Financial Statements